Tandem Diabetes touts pivotal study of insulin pump with low glucose suspend feature

Tandem Diabetes Care (NSDQ:TNDM) touted data today from a pivotal study of its t:slim X2 insulin pump, which features a predictive low glucose suspend feature called Basal-IQ.
The study showed that the system reduced time spent in hypoglycemia by 31% compared to just sensor-augmented pump therapy, according to Tandem.
Get the full story at our sister site, Drug Delivery Business News.
The post Tandem Diabetes touts pivotal study of insulin pump with low glucose suspend feature appeared first on MassDevice.

Source: Mass Device - February 15, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Pharmaceuticals Wall Street Beat tandemdiabetes Source Type: news